Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)

SIMPLE SUMMARY: Over the past decades, the multi-drug approach for treating various types of cancers was highly recommended. The aim of this study was to demonstrate the advantage of treating different carcinoma types with several combinations of immune checkpoint inhibitors (ICIs) and tyrosine kina...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Shalata, Walid, Iraqi, Muhammed, Bhattacharya, Baisali, Fuchs, Vered, Roisman, Laila C., Cohen, Ahron Yehonatan, Massalha, Ismaell, Yakobson, Alexander, Prasad, Manu, Elkabets, Moshe, Porgador, Angel, Peled, Nir
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8307809/
https://ncbi.nlm.nih.gov/pubmed/34298855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13143630
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars